All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your ALL Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
AIEOP-BFM ALL 2009 long-term results: Reduced dose daunorubicin for pediatric patients with B-cell ALL
Bookmark this article
|
The first randomization in the multicenter AIEOP-BFM ALL 2009 trial (NCT01117441; EudraCT 2007-004270-43) assessed the safety and efficacy of two (EA; n = 1,039) vs four (CA; n = 1,040) doses of daunorubicin during induction in ND pediatric patients aged 1 to <18 years with non-high-risk B-ALL.1 Long-term results from this trial were presented at the 66th ASH Annual Meeting and Exposition by Schrappe.1 |
| Key learnings |
|
EFS was similar between patients in the EA vs CA at both 5 years (92.7% vs 92.3%) and 8 years (90.6% vs 91.1%) (p = 0.83). |
| OS was also comparable between patients in the EA vs CA; the 5-year OS was 97.3% vs 97.7% and the 8-year OS was 97.2% vs 97.6% (p = 0.69). |
| The rates of systemic/invasive fungal infections (1.5% vs 0.5%) and sinus venous thrombosis (1.2% vs 0.2%) were higher in the CA vs EA. |
| These results suggest that reducing daunorubicin from two doses to four doses during induction does not comprise efficacy outcomes and may reduce toxicities in ND pediatric patients with B-ALL. |
Abbreviations: ASH, American Society of Hematology; B-ALL, B-cell acute lymphoblastic leukemia; CA, control arm; EA, experimental arm; EFS, event-free survival; ND, newly diagnosed; OS, overall survival.
Schrappe M. A reduced daunorubicin dose during induction is equally effective as standard dose in children with acute lymphoblastic leukemia (ALL) and favorable prognostic features: Long-term results of the phase 3 trial AIEOP-BFM ALL 2009. Oral abstract #309. Presented at: 66th ASH Annual Meeting and Exposition; Dec 7–10, 2024; San Diego, US.
Your opinion matters
14 votes - 22 days left ...
Related articles
Newsletter
Subscribe to get the best content related to ALL delivered to your inbox